With nonprofit MassBiologics discontinuing production of tetanusvaccines, the Centers for Disease Control and Prevention anticipates a shortage of the shots in the U.S. later this year. Sanofi becomes the lone supplier of tetanus vaccines for the U.S.
It’s time to add another vaccine to the shortage list in the U.S. as the Centers for Disease Control and Prevention (CDC) has urged healthcare providers to conserve their supply of tetanus shots.
The warning from the national public health agency comes after one of the two providers of tetanus shots in the U.S., nonprofit MassBiologics, discontinued production of its tetanusand diphtheria (Td) vaccine. MassBiologics’ exclusive distributor, Grifols USA, told the CDC that supply of the product, which is called TdVax, will last until June of this year.
Meanwhile, the other manufacturer of tetanus shots for the U.S., Sanofi, “is taking steps to augment their available supply,” the CDC said.
Tdap vaccines available in the U.S. are Sanofi’s Adacel and GSK’s Boostrix. The shots are more expensive than Td vaccines but have increased in popularity, while sales of Td shots have declined.
Tetanus is a virus caused by bacteria Clostridium, which is often found in soil. The bacteria can cause muscle contractions, especially in the neck and mouth, also referred to a “lockjaw.”
In recent months, the CDC also has dealt with a shortage of a new immunization to combat respiratory syncytial virus (RSV). Called Beyfortus, the antibody from partners Sanofi and AstraZeneca is the lone RSV immunization in the U.S. for infants.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.